Compare MGRC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | SUPN |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 1995 | 2010 |
| Metric | MGRC | SUPN |
|---|---|---|
| Price | $113.86 | $50.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $141.50 | $61.60 |
| AVG Volume (30 Days) | 168.6K | ★ 499.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | ★ $944,235,000.00 | $392,755,000.00 |
| Revenue This Year | $4.69 | $22.72 |
| Revenue Next Year | $4.81 | $18.10 |
| P/E Ratio | $17.90 | ★ N/A |
| Revenue Growth | ★ 3.65 | N/A |
| 52 Week Low | $94.99 | $29.16 |
| 52 Week High | $128.41 | $59.68 |
| Indicator | MGRC | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 48.14 |
| Support Level | $111.27 | $47.43 |
| Resistance Level | $123.14 | $52.25 |
| Average True Range (ATR) | 3.53 | 1.56 |
| MACD | 0.76 | 0.15 |
| Stochastic Oscillator | 72.15 | 56.58 |
McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.